The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information, many of which originate from observational studies. This meta-analysis conducted by the Cholesterol Treatment Trialists’ Collaboration, coordinated from the University of Oxford (United Kingdom), systematically evaluated the causal relationship between statin use and the adverse events listed in prescribing information, using individual participant data from randomized, double-blind clinical trials.
A total of 23 trials including 154,664 patients were analyzed. In the statin versus placebo studies (n = 123,940), the mean age was 63 ± 9 years; 72% were men, 48% had prior vascular disease, and the median follow-up was 4.5 years (IQR 3.1–5.4).
Results: Statins and Adverse Effects: What Does Evidence from Randomized Clinical Trials Show?
Among the 66 adverse events evaluated, only four showed a significant increase associated with statin use compared with the control group: elevation of hepatic transaminases, other biochemical liver abnormalities, changes in urinary composition, and edema. Overall, no significant increase was observed in the remaining 62 events analyzed, including cognitive decline, depression, sleep disorders, peripheral neuropathy, or interstitial lung disease.
Regarding muscle-related effects, these were not analyzed as a primary endpoint in this study, as they had already been evaluated by the same collaboration. The findings confirm that clinically significant myopathy is rare, with an incidence of approximately 1 case per 10,000 person-years, and that there is a small absolute increase in muscle symptoms and new-onset diabetes, particularly during the first year of treatment or among patients with metabolic predisposition.
A dose–response relationship was observed for biochemical liver abnormalities, with a higher frequency in intensive therapy regimens (RR 2.06; 95% CI 1.66–2.57). However, this increase was mainly limited to elevations in liver enzymes and was not accompanied by a significant rise in clinically severe hepatic events such as hepatitis, liver failure, or cholestasis. In contrast, no dose–response relationship was found for edema or urinary abnormalities, further questioning their clinical relevance.
Conclusion: Long-Term Statin Safety
In conclusion, statins are primarily associated with mild biochemical liver abnormalities and with previously recognized muscle and metabolic effects, while most of the adverse events listed in prescribing information show no evidence of causality in controlled clinical trials. These findings reinforce that cardiovascular benefits substantially outweigh the risks and suggest the need to reassess safety information in prescribing materials in order to improve clinical decision-making.
Original Title: Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
